NovaBridge Biosciences (NBP)
NASDAQ: NBP · Real-Time Price · USD
2.250
-0.130 (-5.46%)
At close: May 6, 2026, 4:00 PM EDT
2.290
+0.040 (1.78%)
After-hours: May 6, 2026, 7:55 PM EDT
NovaBridge Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
30
Market Cap
260.21M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 632.00K | 2.18M | - |
| Dec 31, 2022 | -1.55M | -15.40M | - |
| Dec 31, 2021 | 13.85M | -222.30M | -94.14% |
| Dec 31, 2020 | 236.15M | 231.84M | 5,381.19% |
| Dec 31, 2019 | 4.31M | -3.51M | -44.90% |
| Dec 31, 2018 | 7.82M | 6.04M | 340.20% |
| Dec 31, 2017 | 1.78M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cellectis | 79.59M |
| Coherus Oncology | 42.17M |
| Editas Medicine | 40.52M |
| C4 Therapeutics | 35.95M |
| Foghorn Therapeutics | 30.91M |
| Zentalis Pharmaceuticals | 26.87M |
| LENZ Therapeutics | 19.09M |
| Artiva Biotherapeutics | 251.00K |
NBP News
- 14 days ago - NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value - GlobeNewsWire
- 4 weeks ago - NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer - GlobeNewsWire
- 2 months ago - NovaBridge Biosciences Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease - Benzinga
- 2 months ago - NovaBridge Biosciences Transcript: Status update - Transcripts
- 2 months ago - NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study - GlobeNewsWire
- 2 months ago - NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026 - GlobeNewsWire